Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy
ConditionRectal Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Tuebingen
About this trial
This study is testing whether radiation delivered with MRI guidance using a so-called MR-linac in distal rectal cancer can result in a high rate of organ preservation. Patients will receive radiotherapy together with standard chemotherapy.
Eligibility criteria
Qualifiers
Patients with histologically confirmed diagnosis of rectal cancer localized between dentate line and 12 cm from the anocutaneous line
Any MRI staged rectal cancer meeting the following criteria
cT1-cT3 and
cN0 -cN1 and
Disqualifiers
Lower border of the tumor localised more than 12 cm from the anocutaneous line as measured by rigid rectoscopy
Distant metastases
Preexisting fecal incontinence for solid stool
Prior antineoplastic therapy for rectal cancer
Trial design
Treatments tested in this trial
- Dose escalated radiotherapy using a 1.5 T MR-Linac
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov